Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Gibbons is active.

Publication


Featured researches published by Peter Gibbons.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria

Giancarlo A. Biagini; Nicholas S. Fisher; Alison E. Shone; Murad A. Mubaraki; Abhishek Srivastava; Alasdair Hill; Thomas Antoine; Ashley J. Warman; Jill Davies; Chandrakala Pidathala; Richard Amewu; Suet C. Leung; Raman Sharma; Peter Gibbons; David W Hong; Bénédicte Pacorel; Alexandre S. Lawrenson; Sitthivut Charoensutthivarakul; Lee Taylor; Olivier Berger; Alison Mbekeani; Paul A. Stocks; Gemma L. Nixon; James Chadwick; Janet Hemingway; Michael J. Delves; Robert E. Sinden; Anne-Marie Zeeman; Clemens H. M. Kocken; Neil G. Berry

There is an urgent need for new antimalarial drugs with novel mechanisms of action to deliver effective control and eradication programs. Parasite resistance to all existing antimalarial classes, including the artemisinins, has been reported during their clinical use. A failure to generate new antimalarials with novel mechanisms of action that circumvent the current resistance challenges will contribute to a resurgence in the disease which would represent a global health emergency. Here we present a unique generation of quinolone lead antimalarials with a dual mechanism of action against two respiratory enzymes, NADH:ubiquinone oxidoreductase (Plasmodium falciparum NDH2) and cytochrome bc1. Inhibitor specificity for the two enzymes can be controlled subtly by manipulation of the privileged quinolone core at the 2 or 3 position. Inhibitors display potent (nanomolar) activity against both parasite enzymes and against multidrug-resistant P. falciparum parasites as evidenced by rapid and selective depolarization of the parasite mitochondrial membrane potential, leading to a disruption of pyrimidine metabolism and parasite death. Several analogs also display activity against liver-stage parasites (Plasmodium cynomolgi) as well as transmission-blocking properties. Lead optimized molecules also display potent oral antimalarial activity in the Plasmodium berghei mouse malaria model associated with favorable pharmacokinetic features that are aligned with a single-dose treatment. The ease and low cost of synthesis of these inhibitors fulfill the target product profile for the generation of a potent, safe, and inexpensive drug with the potential for eventual clinical deployment in the control and eradication of falciparum malaria.


Journal of Medicinal Chemistry | 2012

Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).

Chandrakala Pidathala; Richard Amewu; Bénédicte Pacorel; Gemma L. Nixon; Peter Gibbons; W. David Hong; Suet C. Leung; Neil G. Berry; Raman Sharma; Paul A. Stocks; Abhishek Srivastava; Alison E. Shone; Sitthivut Charoensutthivarakul; Lee Taylor; Olivier Berger; Alison Mbekeani; Alasdair Hill; Nicholas Fisher; Ashley J. Warman; Giancarlo A. Biagini; Stephen A. Ward; Paul M. O’Neill

A program was undertaken to identify hit compounds against NADH:ubiquinone oxidoreductase (PfNDH2), a dehydrogenase of the mitochondrial electron transport chain of the malaria parasite Plasmodium falciparum. PfNDH2 has only one known inhibitor, hydroxy-2-dodecyl-4-(1H)-quinolone (HDQ), and this was used along with a range of chemoinformatics methods in the rational selection of 17 000 compounds for high-throughput screening. Twelve distinct chemotypes were identified and briefly examined leading to the selection of the quinolone core as the key target for structure–activity relationship (SAR) development. Extensive structural exploration led to the selection of 2-bisaryl 3-methyl quinolones as a series for further biological evaluation. The lead compound within this series 7-chloro-3-methyl-2-(4-(4-(trifluoromethoxy)benzyl)phenyl)quinolin-4(1H)-one (CK-2-68) has antimalarial activity against the 3D7 strain of P. falciparum of 36 nM, is selective for PfNDH2 over other respiratory enzymes (inhibitory IC50 against PfNDH2 of 16 nM), and demonstrates low cytotoxicity and high metabolic stability in the presence of human liver microsomes. This lead compound and its phosphate pro-drug have potent in vivo antimalarial activity after oral administration, consistent with the target product profile of a drug for the treatment of uncomplicated malaria. Other quinolones presented (e.g., 6d, 6f, 14e) have the capacity to inhibit both PfNDH2 and P. falciparum cytochrome bc1, and studies to determine the potential advantage of this dual-targeting effect are in progress.


Journal of Medicinal Chemistry | 2009

Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.

Paul M. O'Neill; B.K. Park; Alison E. Shone; James L. Maggs; P. Roberts; Paul A. Stocks; Giancarlo A. Biagini; Patrick G. Bray; Peter Gibbons; Neil G. Berry; Peter Winstanley; Amira Mukhtar; Richard P. Bonar-Law; Stephen Hindley; Ramesh Bambal; Charles B. Davis; M. Bates; T. K. Hart; S. L. Gresham; R. M. Lawrence; R. A. Brigandi; F. M. Gomez-delas-Heras; Domingo Gargallo; Stephen A. Ward

N-tert-Butyl isoquine (4) (GSK369796) is a 4-aminoquinoline drug candidate selected and developed as part of a public-private partnership between academics at Liverpool, MMV, and GSK pharmaceuticals. This molecule was rationally designed based on chemical, toxicological, pharmacokinetic, and pharmacodynamic considerations and was selected based on excellent activity against Plasmodium falciparum in vitro and rodent malaria parasites in vivo. The optimized chemistry delivered this novel synthetic quinoline in a two-step procedure from cheap and readily available starting materials. The molecule has a full industry standard preclinical development program allowing first into humans to proceed. Employing chloroquine (1) and amodiaquine (2) as comparator molecules in the preclinical plan, the first preclinical dossier of pharmacokinetic, toxicity, and safety pharmacology has also been established for the 4-aminoquinoline antimalarial class. These studies have revealed preclinical liabilities that have never translated into the human experience. This has resulted in the availability of critical information to other drug development teams interested in developing antimalarials within this class.


Journal of Medicinal Chemistry | 2008

Two-step synthesis of achiral dispiro-1,2,4,5-tetraoxanes with outstanding antimalarial activity, low toxicity, and high-stability profiles?

Gemma L. Ellis; Richard Amewu; Sunil Sabbani; Paul A. Stocks; Alison E. Shone; Deborah Stanford; Peter Gibbons; Jill Davies; Livia Vivas; Sarah Charnaud; Emily Bongard; Charlotte Hall; Karen Rimmer; Sonia Lozanom; María Jesús; Domingo Gargallo; Stephen A. Ward; Paul M. O'Neill

A rapid, two-step synthesis of a range of dispiro-1,2,4,5-tetraoxanes with potent antimalarial activity both in vitro and in vivo has been achieved. These 1,2,4,5-tetraoxanes have been proven to be superior to 1,2,4-trioxolanes in terms of stability and to be superior to trioxane analogues in terms of both stability and activity. Selected analogues have in vitro nanomolar antimalarial activity and good oral activity and are nontoxic in screens for both cytotoxicity and genotoxicity. The synthesis of a fluorescent 7-nitrobenza-2-oxa-1,3-diazole (NBD) tagged tetraoxane probe and use of laser scanning confocal microscopy techniques have shown that tagged molecules accumulate selectively only in parasite infected erythrocytes and that intraparasitic formation of adducts could be inhibited by co-incubation with the iron chelator desferrioxamine (DFO).


Bioorganic & Medicinal Chemistry Letters | 2008

Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors

Edite Verissimo; Neil G. Berry; Peter Gibbons; Maria Lurdes Santos Cristiano; Philip J. Rosenthal; Jiri Gut; Stephen A. Ward; Paul M. O'Neill

The structure-based design, chemical synthesis and in vitro activity evaluation of various falcipain inhibitors derived from 2-pyridone are reported. These compounds contain a peptidomimetic binding determinant and a Michael acceptor terminal moiety capable of deactivating the cysteine protease active site.


Journal of Medicinal Chemistry | 2012

Identification of novel antimalarial chemotypes via chemoinformatic compound selection methods for a high-throughput screening program against the novel malarial target, PfNDH2: Increasing hit rate via virtual screening methods

Raman Sharma; Alexandre S. Lawrenson; Nicholas Fisher; Ashley J. Warman; Alison E. Shone; Alasdair Hill; Alison Mbekeani; Chandrakala Pidathala; Richard Amewu; Suet C. Leung; Peter Gibbons; David W Hong; Paul A. Stocks; Gemma L. Nixon; James Chadwick; Joanne Shearer; Ian K. Gowers; David William Cronk; Serge P. Parel; Paul M. O'Neill; Stephen A. Ward; Giancarlo A. Biagini; Neil G. Berry

Malaria is responsible for approximately 1 million deaths annually; thus, continued efforts to discover new antimalarials are required. A HTS screen was established to identify novel inhibitors of the parasites mitochondrial enzyme NADH:quinone oxidoreductase (PfNDH2). On the basis of only one known inhibitor of this enzyme, the challenge was to discover novel inhibitors of PfNDH2 with diverse chemical scaffolds. To this end, using a range of ligand-based chemoinformatics methods, ∼17000 compounds were selected from a commercial library of ∼750000 compounds. Forty-eight compounds were identified with PfNDH2 enzyme inhibition IC50 values ranging from 100 nM to 40 μM and also displayed exciting whole cell antimalarial activity. These novel inhibitors were identified through sampling 16% of the available chemical space, while only screening 2% of the library. This study confirms the added value of using multiple ligand-based chemoinformatic approaches and has successfully identified novel distinct chemotypes primed for development as new agents against malaria.


Malaria Journal | 2010

A novel drug for uncomplicated malaria: targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNdh2) of Plasmodium falciparum

Steve A. Ward; Nicholas Fisher; Alasdair Hill; Alison Mbekeani; Alison E. Shone; Gemma L. Nixon; Paul A. Stocks; Peter Gibbons; Richard Amewu; David W Hong; Victoria Barton; Chandra Pidathala; James Chadwick; Louise Le Pensee; Ashley J. Warman; Raman Sharma; Neil G. Berry; Paul M. O'Neill; Giancarlo A. Biagini

The mitochondrial respiratory chain of the malaria parasite Plasmodium falciparum differs from that of its human host in that it lacks a canonical protonmotive NADH:ubiquinone oxidoreductase (Complex I), containing instead a single sub-unit, non-protonmotive Ndh2, similar to that found in plant mitochondria, fungi and some bacteria [1,2]. As such, the P. falciparum Ndh 2 (PfNdh2) is a potentially attractive anti-malarial chemotherapeutic target. Using an E.coli NADH dehydrogenase knockout strain (ANN0222, ndh::tet nuoB::nptI-sacRB) we have developed a heterologous expression system for PfNdh2, facilitating its physicochemical and enzymological characterisation [2]. PfNdh2 represents a metabolic choke point in the respiratory chain of P. falciparum mitochondria and is the focus of a drug discovery programme towards the development of a novel therapy for uncomplicated malaria. Here we describe a miniaturised spectrophotometric assay for recombinant PfNdh2 (steady state NADH oxidation and ubiquinone reduction monitored at 340 nm and 283 nm respectively) with robust assay performance measures that has been utilised for the high throughput screening (HTS) of small molecule inhibitors. The objectives of the HTS were twofold: (i) Increase the number of selective PfNdh2 inhibitors and (ii) to expand the number of inhibitor chemotypes. At the time of screening, only one proof of concept molecule, 1-hydroxy-2-dodecyl-4-(1H)quinolone (HDQ), was known to have PfNdh2 inhibitory activity (IC50=70 nM) [3,4]. HDQ was used to initiate a primary similarity-based screen of 1000 compounds from a compound collection of 750,000 compounds (curated by Biofocus-DPI). Chemoinformatics methodology was applied to the hits from this initial phase in order to perform a hit expansion screen on a further ~16,000 compounds. Application of this chemoinformatic strategy allowed us to cover ~16% diversity whilst screening just ~2% of the compound collection. The HTS resulted in a hit rate of 0.29% and 1 50 compounds were progressed for potency against PfNdh2. Of these compounds, 50 were considered active with IC50s ranging from 100 nM to 40 μM. Currently seven distinct chemotypes are being progressed from hit to lead using traditional synthetic medicinal chemistry strategies.


Organic and Biomolecular Chemistry | 2010

Synthesis, in vitro and in vivo antimalarial assessment of sulfide, sulfone and vinyl amide-substituted 1,2,4-trioxanes prepared via thiol-olefin co-oxygenation (TOCO) of allylic alcohols

Richard Amewu; Peter Gibbons; Amira Mukhtar; Andrew V. Stachulski; Stephen A. Ward; Charlotte Hall; Karen Rimmer; Jill Davies; Livia Vivas; John Bacsa; Amy E. Mercer; Gemma L. Nixon; Paul A. Stocks; Paul M. O'Neill

Thiol-Olefin Co-Oxygenation (TOCO) methodology has been applied to the synthesis of a small library of weak base and polar 1,2,4-trioxanes. The 1,2,4-trioxane units synthesised exhibit remarkable stability as they survive base catalysed hydrolysis and mixed anhydride/amine coupling reactions. This unique stability feature has enabled a range of novel substitution patterns to be incorporated within the spiro 1,2,4-trioxane unit. Selected analogues express potent in vitro nM antimalarial activity, low cytotoxicity and oral activity in the Plasmodium berghei mouse model of malaria.


Journal of Medicinal Chemistry | 2017

Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis

W. David Hong; Peter Gibbons; Suet C. Leung; Richard Amewu; Paul A. Stocks; Andrew V. Stachulski; Pedro Horta; Maria Lurdes Santos Cristiano; Alison E. Shone; Darren M. Moss; Alison Ardrey; Raman Sharma; Ashley J. Warman; Paul T. P. Bedingfield; Nicholas Fisher; Ghaith Aljayyoussi; Sally Mead; Maxine Caws; Neil G. Berry; Stephen A. Ward; Giancarlo A. Biagini; Paul M. O’Neill; Gemma L. Nixon

A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified ∼100 hits and four distinct chemotypes, the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone library (350 compounds) identified a further ∼90 hits across three quinolone subtemplates. Quinolones containing the amine-based side chain were selected as the pharmacophore for further modification, resulting in metabolically stable quinolones effective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicological profiles.


Chemical Communications | 2006

α-Lithio quinuclidine N-oxide (Li-QNO): A new base for synthetic chemistry

Ian A. O'Neil; Inder Bhamra; Peter Gibbons

A-Lithio quinuclidine N-oxide (Li-QNO) behaves as a strong non-nucleophilic base and an HMPA mimetic in a tandem process, in a range of synthetically useful reactions.

Collaboration


Dive into the Peter Gibbons's collaboration.

Top Co-Authors

Avatar

Paul A. Stocks

Liverpool School of Tropical Medicine

View shared research outputs
Top Co-Authors

Avatar

Stephen A. Ward

Liverpool School of Tropical Medicine

View shared research outputs
Top Co-Authors

Avatar

Giancarlo A. Biagini

Liverpool School of Tropical Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alison E. Shone

Liverpool School of Tropical Medicine

View shared research outputs
Top Co-Authors

Avatar

Gemma L. Nixon

Liverpool School of Tropical Medicine

View shared research outputs
Top Co-Authors

Avatar

Ashley J. Warman

Liverpool School of Tropical Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge